WE CLAIM:

1. An anti-IFNAR2 monoclonal antibody which blocks the binding of a first type I interferon to IFNAR2 and does not block the binding of a second type I interferon to IFNAR2.

2. The antibody of claim 1, wherein the second type I interferon is IFN-β.

3. The antibody of claim 2, wherein the first type I interferon is selected from the group consisting of IFN-αB, IFN-αG, IFN-αA, and IFN-αD.

4. The antibody of claim 3, wherein the antibody blocks the binding of IFN-αB, IFN-αG, IFN-αA, and IFN-αD to IFNAR2.

5. An anti-IFNAR2 monoclonal antibody that competes for binding to IFNAR2 with an antibody selected from the group consisting of 1F3, 3B7 and 1D3.

6. An anti-IFNAR2 monoclonal antibody selected from the group consisting of: (1) an antibody that binds to one or more of amino acid positions 49, 51, 52 and 54 in situ in the extracellular domain of IFNAR2 (amino acid positions 1-216 of SEQ ID NO.26); (2) an antibody that binds to one or more of amino acid positions 68, 71 and 72 in situ in the extracellular domain of IFNAR2 (amino acid positions 1-216 of SEQ ID NO.26); (3) an antibody that binds to one or more of amino acid positions 133, 134, 135 and 139 in situ in the extracellular domain of IFNAR2 (amino acid positions 1-216 of SEQ ID NO.26); (4) an antibody that binds to one or more of amino acid positions 153, 154 and 156 in situ in the extracellular domain of IFNAR2 (amino acid positions 1-216 of SEQ ID NO.26); (5) an antibody that binds to one or more of amino acid positions 74, 77 and 78 in situ in the extracellular domain of IFNAR2 (amino acid positions 1-216 of SEQ ID NO.26); and (6) an antibody that binds to one or more of amino acid

positions 105 and 109 in situ in the extracellular domain of IFNAR2 (amino acid positions 1-216 of SEQ ID NO.26).

7. The anti-IFNAR2 monoclonal antibody of claim 6 that (a) binds to one or more of amino acid positions 68, 71 and 72 in situ in the extracellular domain of IFNAR2 (amino acid positions 1-216 of SEQ ID NO.26); and (b) binds to one or more of amino acid positions 49, 51, 52 and 54 in situ in the extracellular domain of IFNAR2 (amino acid positions 1-216 of SEQ ID NO.26).

8. The anti-IFNAR2 monoclonal antibody of claim 7 that is 3B7.

9. The anti-IFNAR2 monoclonal antibody of claim 6 that (a) binds to one or more of amino acid positions 153, 154 and 156 in situ in the extracellular domain of IFNAR2 (amino acid positions 1-216 of SEQ ID NO.26); and (b) binds to one or more of amino acid positions 133, 134, 135 and 139 in situ in the extracellular domain of IFNAR2 (amino acid positions 1-216 of SEQ ID NO.26).

10. The anti-IFNAR2 monoclonal antibody of claim 9 that is 1D3.

11. The anti-IFNAR2 monoclonal antibody of claim 6 that (a) binds to one or more of amino acid positions 68, 71 and 72 in situ in the extracellular domain of IFNAR2 (amino acid positions 1-216 of SEQ ID NO.26); (b) binds to one or more of amino acid positions 49, 51, 52 and 54 in situ in the extracellular domain of IFNAR2 (amino acid positions 1-216 of SEQ ID NO.26); (c) binds to one or more of amino acid positions 74, 77 and 78 in situ in the extracellular domain of IFNAR2 (amino acid positions 1-216 of SEQ ID NO.26); (d) binds to one or more of amino acid positions 105 and 109 in situ in the extracellular domain of IFNAR2 (amino acid positions 1-216 of SEQ ID NO.26); (e) binds to one or more of amino acid positions 153, 154 and 156 in situ in the extracellular domain of IFNAR2 (amino acid positions 1-216 of SEQ ID NO.26); and (f)

binds to one or more of amino acid positions 133, 134, 135 and 139 in situ in the extracellular domain of IFNAR2 (amino acid positions 1-216 of SEQ ID NO.26).

12. The anti-IFNAR2 monoclonal antibody of claim 11 that is 1F3.